Brea Lipe
YOU?
Author Swipe
View article: Characterization and Management of Cytokine Release Syndrome From the <scp>MonumenTAL</scp> ‐1 Study of Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma
Characterization and Management of Cytokine Release Syndrome From the <span>MonumenTAL</span> ‐1 Study of Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma Open
Introduction Cytokine release syndrome (CRS) is a common adverse event associated with T‐cell redirection therapies (TCRT), including talquetamab, the first GPRC5D × CD3 bispecific antibody approved for relapsed/refractory multiple myeloma…
View article: Infections and parameters of humoral immunity with talquetamab in relapsed/refractory multiple myeloma in MonumenTAL-1
Infections and parameters of humoral immunity with talquetamab in relapsed/refractory multiple myeloma in MonumenTAL-1 Open
Talquetamab is the first approved GPRC5D-targeting bispecific antibody for the treatment of relapsed/refractory multiple myeloma (RRMM), based on results from the phase 1/2 MonumenTAL-1 study. We report the infection profile among patients…
View article: Comparative Effectiveness of Ciltacabtagene Autoleucel in CARTITUDE-4 Versus Real-World Physician’s Choice of Therapy from the Flatiron Registry in Lenalidomide-Refractory Multiple Myeloma
Comparative Effectiveness of Ciltacabtagene Autoleucel in CARTITUDE-4 Versus Real-World Physician’s Choice of Therapy from the Flatiron Registry in Lenalidomide-Refractory Multiple Myeloma Open
View article: Comparative Efficacy of Ciltacabtagene Autoleucel Versus Standard-of-Care Treatments for Patients with Previously Treated Relapsed or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Comparison
Comparative Efficacy of Ciltacabtagene Autoleucel Versus Standard-of-Care Treatments for Patients with Previously Treated Relapsed or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Comparison Open
View article: Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1–2 study
Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1–2 study Open
Janssen.
View article: Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma
Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma Open
Elotuzumab is a monoclonal antibody targeting signaling lymphocyte activation molecule F7 on plasma and natural killer cells, which enhances the activity of lenalidomide, pomalidomide, and bortezomib in multiple myeloma (MM). The OPTIMISMM…
View article: Clinical Management of Patients With Relapsed/Refractory Multiple Myeloma Treated With Talquetamab
Clinical Management of Patients With Relapsed/Refractory Multiple Myeloma Treated With Talquetamab Open
Although talquetamab had a distinct safety profile, AEs were considered clinically manageable and mostly low grade. With appropriate education and support, health care practitioners can ensure patients with RRMM maintain quality of life an…
View article: Post-translational regulation of Platelet-derived growth factor receptor β is critical for fracture repair in aged mice
Post-translational regulation of Platelet-derived growth factor receptor β is critical for fracture repair in aged mice Open
Increased protein ubiquitination was observed in fracture callus and particularly in aged mice. Treatment of proteasome inhibitor enhanced fracture repair in young and mice by increasing the number of mesenchymal progenitor cells (MPCs). H…
View article: Senescent cells impair fracture repair through elevating ubiquitin-proteasome system activity in aged mice
Senescent cells impair fracture repair through elevating ubiquitin-proteasome system activity in aged mice Open
Senescent cells accumulate in multiple tissues with aging. Depletion of senescent cells benefits the aging related disease, such as aging bone fracture. However, the molecular mechanisms by which senescent cells regulate their neighboring …
View article: MM-191 Analysis of Infections and Parameters of Humoral Immunity in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With Talquetamab (tal) Monotherapy in MonumenTAL-1
MM-191 Analysis of Infections and Parameters of Humoral Immunity in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With Talquetamab (tal) Monotherapy in MonumenTAL-1 Open
View article: P892: ANALYSIS OF INFECTIONS AND PARAMETERS OF HUMORAL IMMUNITY IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH TALQUETAMAB (TAL) MONOTHERAPY IN MONUMENTAL-1
P892: ANALYSIS OF INFECTIONS AND PARAMETERS OF HUMORAL IMMUNITY IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH TALQUETAMAB (TAL) MONOTHERAPY IN MONUMENTAL-1 Open
Topic: 14. Myeloma and other monoclonal gammopathies - Clinical Background: Infection, a key complication of MM, may be due to patient, disease, or treatment-related factors. Immunotherapies that impact normal immune cells may increase ris…
View article: P1685: PATIENTS’ PREFERENCES FOR MULTIPLE MYELOMA (MM) TREATMENT INITIATION AND DISCONTINUATION IN THE US
P1685: PATIENTS’ PREFERENCES FOR MULTIPLE MYELOMA (MM) TREATMENT INITIATION AND DISCONTINUATION IN THE US Open
Topic: 35. Quality of life and palliative care Background: Patients with MM and their clinicians face difficult choices between treatments that differ in their benefits, risks, and mode of administration. Patients have increased satisfacti…
View article: Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies
Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies Open
Selinexor-based regimens may offer effective and well-tolerated therapy to patients with relapsed and/or refractory MM who had disease previously exposed or refractory to αCD38 mAb therapy and could help address the unmet clinical need in …
View article: Data from Lipoprotein Lipase Links Dietary Fat to Solid Tumor Cell Proliferation
Data from Lipoprotein Lipase Links Dietary Fat to Solid Tumor Cell Proliferation Open
Many types of cancer cells require a supply of fatty acids (FA) for growth and survival, and interrupting de novo FA synthesis in model systems causes potent anticancer effects. We hypothesized that, in addition to synthesis, cancer…
View article: Supplementary Figures 1-3, Table 1 from Lipoprotein Lipase Links Dietary Fat to Solid Tumor Cell Proliferation
Supplementary Figures 1-3, Table 1 from Lipoprotein Lipase Links Dietary Fat to Solid Tumor Cell Proliferation Open
Supplementary Figures 1-3, Table 1 from Lipoprotein Lipase Links Dietary Fat to Solid Tumor Cell Proliferation
View article: Data from Lipoprotein Lipase Links Dietary Fat to Solid Tumor Cell Proliferation
Data from Lipoprotein Lipase Links Dietary Fat to Solid Tumor Cell Proliferation Open
Many types of cancer cells require a supply of fatty acids (FA) for growth and survival, and interrupting de novo FA synthesis in model systems causes potent anticancer effects. We hypothesized that, in addition to synthesis, cancer…
View article: Supplementary Figures 1-3, Table 1 from Lipoprotein Lipase Links Dietary Fat to Solid Tumor Cell Proliferation
Supplementary Figures 1-3, Table 1 from Lipoprotein Lipase Links Dietary Fat to Solid Tumor Cell Proliferation Open
Supplementary Figures 1-3, Table 1 from Lipoprotein Lipase Links Dietary Fat to Solid Tumor Cell Proliferation
View article: The roles of bone remodeling in normal hematopoiesis and age-related hematological malignancies
The roles of bone remodeling in normal hematopoiesis and age-related hematological malignancies Open
Prior research establishing that bone interacts in coordination with the bone marrow microenvironment (BMME) to regulate hematopoietic homeostasis was largely based on analyses of individual bone-associated cell populations. Recent advance…
View article: JAAD Case Reports article list
JAAD Case Reports article list Open
View article: Onychomadesis and palmoplantar keratoderma associated with talquetamab therapy for relapsed and refractory multiple myeloma
Onychomadesis and palmoplantar keratoderma associated with talquetamab therapy for relapsed and refractory multiple myeloma Open
Talquetamab is a first-in-class humanized antibody that targets both the G protein-coupled receptor class 5 member D (GPRC5D), a novel orphan receptor on malignant plasma cells, and CD3, a receptor present in T cells.1 This bispecific T-ce…
View article: Selinexor‐based regimens in patients with multiple myeloma after prior anti‐B‐cell maturation antigen treatment
Selinexor‐based regimens in patients with multiple myeloma after prior anti‐B‐cell maturation antigen treatment Open
There is a lack of consensus on therapy sequencing in previously treated multiple myeloma, particularly after anti‐B‐cell maturation antigen (BCMA) therapy. Earlier reports on selinexor (X) regimens demonstrated considerable efficacy in ea…
View article: P965: FOLLOW-UP ANALYSIS OF THE RANDOMIZED PHASE II TRIAL OF BORTEZOMIB, LENALIDOMIDE, DEXAMTHASONE WITH/WITHOUT ELOTUZUMAB FOR NEWLY DIAGNOSED, HIGH RISK MULTIPLE MYELOMA (SWOG-1211)
P965: FOLLOW-UP ANALYSIS OF THE RANDOMIZED PHASE II TRIAL OF BORTEZOMIB, LENALIDOMIDE, DEXAMTHASONE WITH/WITHOUT ELOTUZUMAB FOR NEWLY DIAGNOSED, HIGH RISK MULTIPLE MYELOMA (SWOG-1211) Open
Background: The introduction of immunomodulatory agents, proteasome inhibitors, and autologous stem cell transplantation (ASCT) has improved outcomes for patients with multiple myeloma (MM), but those with high risk MM (HRMM) have a poor l…
View article: Cell-free DNA for the detection of emerging treatment failure in relapsed/ refractory multiple myeloma
Cell-free DNA for the detection of emerging treatment failure in relapsed/ refractory multiple myeloma Open
View article: Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients
Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients Open
Background Proteasome inhibitors (PIs), including carfilzomib, potentiate the activity of selinexor, a novel, first-in-class, oral selective inhibitor of nuclear export (SINE) compound, in preclinical models of multiple myeloma (MM). Metho…
View article: SOHO State of the Art Updates and Next Questions: Treatment of Older, Vulnerable Adults with Multiple Myeloma
SOHO State of the Art Updates and Next Questions: Treatment of Older, Vulnerable Adults with Multiple Myeloma Open
View article: Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial
Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial Open
View article: Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma
Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma Open
We assessed the safety, efficacy, maximum tolerated dose (MTD), and the recommended phase 2 dose (RP2D) of selinexor, a first in class oral selective inhibitor of nuclear export (100 mg once weekly [QW] or 60 mg twice weekly), in combinati…
View article: Bisphosphonates for delivering drugs to bone
Bisphosphonates for delivering drugs to bone Open
Advances in the design of potential bone‐selective drugs for the treatment of various bone‐related diseases are creating exciting new directions for multiple unmet medical needs. For bone‐related cancers, off‐target/non‐bone toxicities wit…
View article: Management of Frail Older Adults with Newly Diagnosed Multiple Myeloma — Moving Toward a Personalized Approach
Management of Frail Older Adults with Newly Diagnosed Multiple Myeloma — Moving Toward a Personalized Approach Open
View article: Integrating Touchscreen-Based Geriatric Assessment and Frailty Screening for Adults With Multiple Myeloma to Drive Personalized Treatment Decisions
Integrating Touchscreen-Based Geriatric Assessment and Frailty Screening for Adults With Multiple Myeloma to Drive Personalized Treatment Decisions Open
PURPOSE: Geriatric assessment (GA) results predict toxicity/survival in older adults, yet GA is not routinely used in care for patients with multiple myeloma (MM). We tested a tablet-based modified GA (mGA) providing real-time results to c…